Press Releases

05.01.2018

Pfizer Reports First-Quarter 2018 Results

04.26.2018

Pfizer Hosts Annual Meeting of Shareholders

04.23.2018

Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years

04.23.2018

Pfizer Provides Update on Proposed Trastuzumab Biosimilar

04.23.2018

MYLOTARG™ Approved In The EU For The Treatment Of Previously Untreated, De Novo, CD33-positive Acute Myeloid Leukemia In Combination With Chemotherapy

04.19.2018

Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders

04.12.2018

Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

04.10.2018

Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery

04.10.2018

Pfizer Signs Lease for The Spiral at Hudson Yards in Manhattan

04.04.2018

U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

04.03.2018

Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

03.29.2018

Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy